Giancarlo Logroscino

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7383345/publications.pdf

Version: 2024-02-01

344 papers	44,362 citations	4960 84 h-index	2385 198 g-index
348 all docs	348 docs citations	348 times ranked	59045 citing authors

#	Article	IF	Citations
1	Global, regional, and national prevalence of overweight and obesity in children and adults during 1980â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 766-781.	13.7	9,122
2	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
3	Global, regional, and national burden of Parkinson's disease, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 939-953.	10.2	1,573
4	Global, regional, and national burden of neurological disorders during 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurology, The, 2017, 16, 877-897.	10.2	1,521
5	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 88-106.	10.2	1,512
6	Adherence to a DASH-Style Diet and Risk of Coronary Heart Disease and Stroke in Women. Archives of Internal Medicine, 2008, 168, 713.	3.8	1,118
7	Amyotrophic lateral sclerosis. Nature Reviews Disease Primers, 2017, 3, 17071.	30.5	885
8	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 310-323.	2.1	839
9	Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia, 2011, 52, 2-26.	5.1	836
10	A critical appraisal of amyloid-Î²-targeting therapies for AlzheimerÂdisease. Nature Reviews Neurology, 2019, 15, 73-88.	10.1	666
11	Incidence of amyotrophic lateral sclerosis in Europe. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 385-390.	1.9	648
12	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 957-979.	13.7	609
13	Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney International, 2013, 84, 179-191.	5.2	565
14	Accuracy of clinical diagnosis of Parkinson disease. Neurology, 2016, 86, 566-576.	1.1	547
15	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
16	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
17	Prognostication after cardiac arrest and hypothermia: A prospective study. Annals of Neurology, 2010, 67, 301-307.	5.3	488
18	Migraine and Risk of Cardiovascular Disease in Women. JAMA - Journal of the American Medical Association, 2006, 296, 283.	7.4	478

#	Article	IF	Citations
19	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
20	Primary Prevention of Stroke by Healthy Lifestyle. Circulation, 2008, 118, 947-954.	1.6	393
21	Refractory Status Epilepticus. Archives of Neurology, 2005, 62, 1698.	4.5	369
22	Refractory status epilepticus: A prospective observational study. Epilepsia, 2010, 51, 251-256.	5.1	331
23	Status Epilepticus Severity Score (STESS). Journal of Neurology, 2008, 255, 1561-1566.	3.6	326
24	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
25	Shortâ€Term Mortality After a First Episode of Status Epilepticus. Epilepsia, 1997, 38, 1344-1349.	5.1	286
26	Prospective study of dietary pattern and risk of Parkinson disease. American Journal of Clinical Nutrition, 2007, 86, 1486-1494.	4.7	281
27	Three Decades of Comprehensive Geriatric Assessment: Evidence Coming From Different Healthcare Settings and Specific Clinical Conditions. Journal of the American Medical Directors Association, 2017, 18, 192.e1-192.e11.	2.5	277
28	Dietary lipids and antioxidants in Parkinson's disease: A populationâ€based, caseâ€control study. Annals of Neurology, 1996, 39, 89-94.	5.3	263
29	Burden of Neurological Disorders Across the US From 1990-2017. JAMA Neurology, 2021, 78, 165.	9.0	262
30	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimerâ€™s Disease and Late-Life Cognitive Disorders: A Systematic Review. Journal of Alzheimer's Disease, 2017, 59, 815-849.	2.6	249
31	Cigarette smoking and the progression of multiple sclerosis. Brain, 2005, 128, 1461-1465.	7.6	242
32	Risk of unprovoked seizure after acute symptomatic seizure: Effect of status epilepticus. Annals of Neurology, 1998, 44, 908-912.	5.3	241
33	Diet and Alzheimerâ€™s disease risk factors or prevention: the current evidence. Expert Review of Neurotherapeutics, 2011, 11, 677-708.	2.8	231
34	The burden of premature mortality of epilepsy in highâ€income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia, 2017, 58, 17-26.	5.1	228
35	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
36	Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology, 2009, 72, 432-438.	1.1	222

#	Article	IF	Citations
37	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. Journal of Alzheimer's Disease, 2018, 62, 993-1012.	2.6	214
38	Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ: British Medical Journal, 2008, 337, a636-a636.	2.3	211
39	Migraine and Risk of Cardiovascular Disease in Men. Archives of Internal Medicine, 2007, 167, 795.	3.8	202
40	Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. International Journal of Epidemiology, 2017, 46, dyw061.	1.9	202
41	Age-related hearing impairmentâ€"a risk factor and frailty marker for dementia and AD. Nature Reviews Neurology, 2015, 11, 166-175.	10.1	192
42	A clinical score for prognosis of status epilepticus in adults. Neurology, 2006, 66, 1736-1738.	1.1	185
43	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain, 2012, 135, 784-793.	7.6	182
44	Prospective Study of Type 1 and Type 2 Diabetes and Risk of Stroke Subtypes: The Nurses' Health Study. Diabetes Care, 2007, 30, 1730-1735.	8.6	175
45	The epidemiology of ALS and the role of population-based registries. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 1150-1157.	3.8	168
46	Dietary Flavonoids and Risk of Stroke in Women. Stroke, 2012, 43, 946-951.	2.0	167
47	Global, regional, and national burden of motor neuron diseases 1990â€"2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 1083-1097.	10.2	163
48	Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ: British Medical Journal, 2004, 328, 548.	2.3	162
49	Gout and risk of Parkinson disease. Neurology, 2007, 69, 1696-1700.	1.1	158
50	Mortality after a First Episode of Status Epilepticus in the United States and Europe. Epilepsia, 2005, 46, 46-48.	5.1	157
51	Behavioral and Psychological Effects of Coronavirus Disease-19 Quarantine in Patients With Dementia. Frontiers in Psychiatry, 2020, 11, 578015.	2.6	157
52	Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: A systematic review. Journal of Nutrition, Health and Aging, 2015, 19, 313-328.	3.3	154
53	Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease. Diabetes Care, 2008, 31, 2003-2005.	8.6	147
54	Longâ€term survival in amyotrophic lateral sclerosis: A populationâ€based study. Annals of Neurology, 2014, 75, 287-297.	5.3	141

#	Article	IF	Citations
55	A Prospective Cohort Study of Cancer Incidence Following the Diagnosis of Parkinson's Disease. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1260-1265.	2.5	140
56	Cigarette Smoking and Dementia. Epidemiology, 2008, 19, 448-450.	2.7	140
57	Migraine frequency and risk of cardiovascular disease in women. Neurology, 2009, 73, 581-588.	1.1	140
58	Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging. Alzheimer's and Dementia, 2013, 9, 113-122.	0.8	140
59	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimerâ€™s Disease. BioMed Research International, 2016, 2016, 1-15.	1.9	138
60	Association Between Depression and Death in People With CKD: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases, 2013, 62, 493-505.	1.9	137
61	Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ: British Medical Journal, 2008, 337, a2467-a2467.	2.3	136
62	Coffee Consumption and Risk of Stroke in Women. Circulation, 2009, 119, 1116-1123.	1.6	135
63	Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology, 2006, 66, 1097-1099.	1.1	133
64	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. Journal of the American Medical Directors Association, 2017, 18, 89.e1-89.e8.	2.5	126
65	Immunotherapy for Alzheimerâ€™s disease: from anti-Î²-amyloid to tau-based immunization strategies. Immunotherapy, 2012, 4, 213-238.	2.0	121
66	Premature mortality of epilepsy in lowâ€•and middleâ€•income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia, 2017, 58, 6-16.	5.1	120
67	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
68	The Role of Early Life Environmental Risk Factors in Parkinson Disease: What Is the Evidence?. Environmental Health Perspectives, 2005, 113, 1234-1238.	6.0	117
69	Smoking and Risk of Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 207-13.	4.5	117
70	Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition. Rejuvenation Research, 2015, 18, 389-412.	1.8	112
71	Amyotrophic lateral sclerosis, physical exercise, trauma and sports: Results of a population-based pilot case-control study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 289-292.	2.1	110
72	Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. Journal of Alzheimer's Disease, 2015, 47, 793-813.	2.6	108

#	Article	IF	Citations
73	The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 1-10.	2.1	107
74	Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 358-366.	1.9	106
75	Vitamin E Intake and Risk of Amyotrophic Lateral Sclerosis: A Pooled Analysis of Data From 5 Prospective Cohort Studies. American Journal of Epidemiology, 2011, 173, 595-602.	3.4	103
76	Erectile Function and Risk of Parkinson's Disease. American Journal of Epidemiology, 2007, 166, 1446-1450.	3.4	102
77	The Prevalence of Peripheral and Central Hearing Impairment and Its Relation to Cognition in Older Adults. Audiology and Neuro-Otology, 2014, 19, 10-14.	1.3	102
78	Time Trends in Incidence, Mortality, and Case-Fatality after First Episode of Status Epilepticus. Epilepsia, 2001, 42, 1031-1035.	5.1	101
79	Factors predicting survival in ALS: a multicenter Italian study. Journal of Neurology, 2017, 264, 54-63.	3.6	96
80	Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nature Medicine, 2021, 27, 1197-1204.	30.7	96
81	Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1249-1252.	1.9	92
82	Depression and Incident Stroke in Women. Stroke, 2011, 42, 2770-2775.	2.0	91
83	Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?. International Journal of Geriatric Psychiatry, 2012, 27, 1218-1238.	2.7	90
84	Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. American Journal of Geriatric Psychiatry, 2017, 25, 1236-1248.	1.2	90
85	The changing picture of amyotrophic lateral sclerosis: lessons from European registers. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 557-563.	1.9	89
86	Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. European Journal of Epidemiology, 2016, 31, 229-245.	5.7	87
87	Therapeutic intervention for Alzheimer's disease with Î³-secretase inhibitors: still a viable option?. Expert Opinion on Investigational Drugs, 2011, 20, 325-341.	4.1	86
88	Sleep disorders and the natural history of Parkinson's disease: The contribution of epidemiological studies. Sleep Medicine Reviews, 2011, 15, 41-50.	8.5	86
89	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Review of Clinical Immunology, 2014, 10, 405-419.	3.0	86
90	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. Current Opinion in Psychiatry, 2014, 27, 128-137.	6.3	86

#	Article	IF	Citations
91	Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: A population-based study. Journal of the Neurological Sciences, 2006, 250, 45-49.	0.6	85
92	The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey. Frontiers in Aging Neuroscience, 2020, 12, 625781.	3.4	85
93	Dietary Iron Intake and Risk of Parkinson's Disease. American Journal of Epidemiology, 2008, 168, 1381-1388.	3.4	83
94	Amyotrophic Lateral Sclerosis Descriptive Epidemiology: The Origin of Geographic Difference. Neuroepidemiology, 2019, 52, 93-103.	2.3	82
95	Physical activity and amyotrophic lateral sclerosis: A European populationâ€based caseâ€“control study. Annals of Neurology, 2014, 75, 708-716.	5.3	79
96	A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study. Orphanet Journal of Rare Diseases, 2012, 7, 33.	2.7	78
97	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiology of Aging, 2012, 33, 1848.e15-1848.e20.	3.1	76
98	Cortical Thinning and Clinical Heterogeneity in Amyotrophic Lateral Sclerosis. PLoS ONE, 2013, 8, e80748.	2.5	76
99	Mediterranean Diet in Predementia and Dementia Syndromes. Current Alzheimer Research, 2011, 8, 520-542.	1.4	73
100	Classification of Single Normal and Alzheimer's Disease Individuals from Cortical Sources of Resting State EEG Rhythms. Frontiers in Neuroscience, 2016, 10, 47.	2.8	73
101	Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism and Related Disorders, 2013, 19, 980-985.	2.2	72
102	Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology, 2012, 79, 2315-2320.	1.1	70
103	The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear. Frontiers in Neuroscience, 2019, 13, 619.	2.8	70
104	The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990â€“2019: Findings from the Global Burden of Disease Study 2019. Lancet Regional Health - Europe, The, 2022, 16, 100341.	5.6	70
105	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 397-405.	1.7	68
106	Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231881100.	2.5	68
107	Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms. Frontiers in Aging Neuroscience, 2015, 7, 113.	3.4	67
108	Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. BMJ: British Medical Journal, 2011, 342, d198-d198.	2.3	66

#	Article	IF	Citations
109	BACE inhibitors in clinical development for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	2.8	66
110	ALS multidisciplinary clinic and survival. Journal of Neurology, 2007, 254, 1107-1112.	3.6	65
111	Predictors of long survival in amyotrophic lateral sclerosis: A population-based study. Journal of the Neurological Sciences, 2008, 268, 28-32.	0.6	65
112	REVIEW: Î³â€Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. CNS Neuroscience and Therapeutics, 2010, 16, 272-284.	3.9	63
113	Amyloid-directed monoclonal antibodies for the treatment of Alzheimerâ€™s disease: the point of no return?. Expert Opinion on Biological Therapy, 2014, 14, 1465-1476.	3.1	63
114	The Heterogeneity of Amyotrophic Lateral Sclerosis: A Possible Explanation of Treatment Failure. Current Medicinal Chemistry, 2007, 14, 3185-3200.	2.4	62
115	Can Mortality Data Be Used to Estimate Amyotrophic Lateral Sclerosis Incidence?. Neuroepidemiology, 2011, 36, 29-38.	2.3	61
116	Tau-based therapeutics for Alzheimerâ€™s disease: active and passive immunotherapy. Immunotherapy, 2016, 8, 1119-1134.	2.0	61
117	FNDC5/Irisin System in Neuroinflammation and Neurodegenerative Diseases: Update and Novel Perspective. International Journal of Molecular Sciences, 2021, 22, 1605.	4.1	61
118	Folate Intake and Risk of Parkinson's Disease. American Journal of Epidemiology, 2004, 160, 368-375.	3.4	60
119	Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiology of Aging, 2005, 26, 475-484.	3.1	59
120	Reliability of the El Escorial Diagnostic Criteria for Amyotrophic Lateral Sclerosis. Neuroepidemiology, 2002, 21, 265-270.	2.3	58
121	Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. Ageing Research Reviews, 2012, 11, 87-103.	10.9	57
122	Development of the Standards of Reporting of Neurological Disorders (STROND) checklist. Neurology, 2015, 85, 821-828.	1.1	57
123	Prevalence of dementia in the oldest old: The Monzino 80â€plus population based study. Alzheimer's and Dementia, 2015, 11, 258.	0.8	56
124	Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. Journal of Neurology, 2015, 262, 593-603.	3.6	56
125	Emerging drugs to reduce abnormal Î²-amyloid protein in Alzheimerâ€™s disease patients. Expert Opinion on Emerging Drugs, 2016, 21, 377-391.	2.4	54
126	Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides. Neuroscience and Biobehavioral Reviews, 2021, 127, 193-211.	6.1	54

#	Article	IF	Citations
127	Hyperhomocysteinemia in levodopaâ€treated patients with Parkinson's disease dementia. Movement Disorders, 2009, 24, 1028-1033.	3.9	53
128	Body Mass Index and Risk of Parkinson's Disease: A Prospective Cohort Study. American Journal of Epidemiology, 2007, 166, 1186-1190.	3.4	52
129	Prevalence and patterns of cognitive impairment in adult hemodialysis patients: the COGNITIVE-HD study. Nephrology Dialysis Transplantation, 2018, 33, 1197-1206.	0.7	52
130	Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab. Current Alzheimer Research, 2011, 8, 808-817.	1.4	51
131	Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. Age, 2012, 34, 507-517.	3.0	51
132	Coffee Consumption Habits and the Risk ofÂMild Cognitive Impairment: The Italian Longitudinal Study on Aging. Journal of Alzheimer's Disease, 2015, 47, 889-899.	2.6	51
133	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: A Study Using Artificial Neural Networks. Frontiers in Neuroscience, 2016, 10, 604.	2.8	51
134	Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role. American Journal of Epidemiology, 2011, 174, 1002-1008.	3.4	50
135	Are antibodies directed against amyloid-Î² (AÎ²) oligomers the last call for the AÎ² hypothesis of Alzheimer's disease?. Immunotherapy, 2019, 11, 3-6.	2.0	50
136	Prospective caseâ€“control study of nonfatal cancer preceding the diagnosis of parkinsonâ€™s disease. Cancer Causes and Control, 2007, 18, 705-711.	1.8	49
137	COVID-19 Infection and Neurological Complications: Present Findings and Future Predictions. Neuroepidemiology, 2020, 54, 364-369.	2.3	49
138	Perceived imbalance and risk of Parkinson's disease. Movement Disorders, 2008, 23, 613-616.	3.9	48
139	Homocysteine levels and amyotrophic lateral sclerosis: A possible link. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 140-147.	2.1	48
140	An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. Journal of Neurology, 2011, 258, 238-243.	3.6	48
141	Benefits, pitfalls, and future design of population-based registers in neurodegenerative disease. Neurology, 2017, 88, 2321-2329.	1.1	48
142	A case-control study of hormonal exposures as etiologic factors for ALS in women. Neurology, 2017, 89, 1283-1290.	1.1	48
143	Plasma Inflammatory Cytokines Are Elevated in ALS. Frontiers in Neurology, 2020, 11, 552295.	2.4	48
144	Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study. BMC Neurology, 2010, 10, 6.	1.8	47

#	Article	IF	Citations
145	Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques. Journal of the Neurological Sciences, 2014, 347, 39-43.	0.6	47
146	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. Alzheimer's and Dementia, 2019, 15, 1019-1028.	0.8	47
147	Extracorporeal Shock Wave Therapy for the Treatment of Poststroke Plantar-Flexor Muscles Spasticity: A Prospective Open-Label Study. Topics in Stroke Rehabilitation, 2014, 21, S17-S24.	1.9	46
148	Age-specific ALS incidence: a doseâ€“response meta-analysis. European Journal of Epidemiology, 2018, 33, 621-634.	5.7	46
149	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
150	Multicentre, cross-cultural, population-based, caseâ€“control study of physical activity as risk factor for amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 797-803.	1.9	45
151	Current Epidemiological Approaches to the Metabolic-Cognitive Syndrome. Journal of Alzheimer's Disease, 2012, 30, S31-S75.	2.6	44
152	Progresses in treating agitation: a major clinical challenge in Alzheimerâ€™s disease. Expert Opinion on Pharmacotherapy, 2015, 16, 2581-2588.	1.8	43
153	Pharmacotherapy for the treatment of depression in patients with alzheimerâ€™s disease: a treatment-resistant depressive disorder. Expert Opinion on Pharmacotherapy, 2018, 19, 823-842.	1.8	43
154	Morbidity of Nonfebrile Status Epilepticus in Rochester, Minnesota, 1965-1984. Epilepsia, 1998, 39, 829-832.	5.1	42
155	Amyotrophic lateral sclerosis in Catalonia: A population based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 278-283.	1.7	42
156	Efficacy and safety studies of gantenerumab in patients with Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2014, 14, 973-986.	2.8	42
157	Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke. Journal of the Neurological Sciences, 2015, 350, 1-6.	0.6	42
158	Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. Journal of Alzheimer's Disease, 2018, 65, 989-1000.	2.6	42
159	A prospective study of alcoholism and the risk of Parkinson?s disease. Journal of Neurology, 2004, 251, vii14-vii17.	3.6	41
160	Risk of Guillain-BarrÃ© syndrome after 2010â€“2011 influenza vaccination. European Journal of Epidemiology, 2013, 28, 433-444.	5.7	41
161	Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. Journal of Alzheimer's Disease, 2017, 59, 121-130.	2.6	41
162	Apolipoprotein E genotype does not influence the progression of multiple sclerosis. Journal of Neurology, 2003, 250, 1094-1098.	3.6	40

#	Article	IF	Citations
163	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiology of Aging, 2016, 43, 180.e1-180.e5.	3.1	40
164	Cognitive frailty: a potential target for secondary prevention of dementia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1023-1027.	3.3	40
165	Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study. Nutrients, 2020, 12, 426.	4.1	40
166	Methodologic Issues in Studies of Mortality Following Epilepsy: Measures, Types of Studies, Sources of Cases, Cohort Effects, and Competing Risks. Epilepsia, 2005, 46, 3-7.	5.1	39
167	Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 163-167.	2.1	39
168	Population-Based Evidence that Survival in Amyotrophic Lateral Sclerosis Is Related to Weight Loss at Diagnosis. Neurodegenerative Diseases, 2016, 16, 225-234.	1.4	39
169	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
170	Ageâ€Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy. Otolaryngology - Head and Neck Surgery, 2020, 163, 348-355.	1.9	39
171	Being the Family Caregiver of a Patient With Dementia During the Coronavirus Disease 2019 Lockdown. Frontiers in Aging Neuroscience, 2021, 13, 653533.	3.4	39
172	Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review. Journal of Alzheimer's Disease, 2018, 64, S229-S254.	2.6	38
173	Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology, 2016, 87, 237-238.	1.1	36
174	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Review of Proteomics, 2017, 14, 809-824.	3.0	36
175	Telemedicine is a useful tool to deliver care to patients with Amyotrophic Lateral Sclerosis during COVID-19 pandemic: results from Southern Italy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 542-548.	1.7	36
176	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age, 2013, 35, 441-453.	3.0	35
177	Development of the standards of reporting of neurological disorders (STROND) checklist: a guideline for the reporting of incidence and prevalence studies in neuroepidemiology. European Journal of Epidemiology, 2015, 30, 569-576.	5.7	35
178	Warfarin Treatment and Allâ€Cause Mortality in Communityâ€Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. Journal of the American Geriatrics Society, 2016, 64, 1416-1424.	2.6	35
179	Tau-directed approaches for the treatment of Alzheimerâ€™s disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics, 2016, 16, 259-277.	2.8	35
180	Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Frontiers in Neuroscience, 2019, 13, 485.	2.8	35

#	Article	IF	Citations
181	Incidence of frontotemporal lobar degeneration in Italy. Neurology, 2019, 92, e2355-e2363.	1.1	35
182	Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy. Journal of Alzheimer's Disease, 2020, 76, 481-489.	2.6	35
183	Environmental Issues and Neurological Manifestations Associated with COVID-19 Pandemic: New Aspects of the Disease?. International Journal of Environmental Research and Public Health, 2020, 17, 8049.	2.6	35
184	Blood donations, iron stores, and risk of Parkinson's disease. Movement Disorders, 2006, 21, 835-838.	3.9	34
185	The potential of solanezumab and gantenerumab to prevent Alzheimerâ€™s disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy, 2018, 18, 25-35.	3.1	34
186	Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 176-185.	1.7	34
187	Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins, 2015, 7, 3045-3056.	3.4	33
188	Status Epilepticus Without an Underlying Cause and Risk of Death. Archives of Neurology, 2008, 65, 221-4.	4.5	32
189	FUS mutations in sporadic amyotrophic lateral sclerosis: Clinical and genetic analysis. Neurobiology of Aging, 2012, 33, 837.e1-837.e5.	3.1	32
190	Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. Journal of Neural Transmission, 2013, 120, 469-476.	2.8	32
191	Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 879-886.	1.9	32
192	Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial. Clinical Rehabilitation, 2015, 29, 50-58.	2.2	32
193	Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 485-495.	1.7	32
194	Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 561.	2.2	31
195	Treatment of Nonfebrile Status Epilepticus in Rochester, Minn, From 1965 Through 1984. Mayo Clinic Proceedings, 2001, 76, 39-41.	3.0	29
196	Natural history of upper motor neuron-dominant ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 424-429.	2.1	29
197	Serum <emph type="ital">N</emph> -acetylaspartate Level in Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 1308.	4.5	29
198	The Role of Biomarkers in Psychiatry. Advances in Experimental Medicine and Biology, 2019, 1118, 135-162.	1.6	29

#	Article	IF	Citations
199	Hospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population-based cohort study. BMC Pulmonary Medicine, 2016, 16, 136.	2.0	28
200	A Multicentric Prospective Incidence Study of Guillain-BarrÃ© Syndrome in Italy. The ITANG Study. Neuroepidemiology, 2015, 45, 90-99.	2.3	27
201	Stratification of ALS patientsâ€™ survival: a population-based study. Journal of Neurology, 2016, 263, 100-111.	3.6	27
202	Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review. Neuroscience and Biobehavioral Reviews, 2018, 95, 480-498.	6.1	27
203	Interacting with γSecretase for Treating Alzheimer's Disease: From Inhibition to Modulation. Current Medicinal Chemistry, 2011, 18, 5430-5447.	2.4	26
204	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 118-125.	1.7	26
205	Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 11-19.	1.9	26
206	Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational study. BMJ Open, 2015, 5, e007069.	1.9	25
207	An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities. Rejuvenation Research, 2018, 21, 3-14.	1.8	25
208	Heterogeneous models for blood-cerebrospinal fluid barrier permeability to serum proteins in normal and abnormal cerebrospinal fluid/serum protein concentration gradients. Journal of the Neurological Sciences, 1984, 64, 245-258.	0.6	24
209	A Population-based study of dementia in the oldest old: the Monzino 80-plus Study. BMC Neurology, 2011, 11, 54.	1.8	24
210	Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. Alzheimer's and Dementia, 2017, 13, 858-869.	0.8	24
211	Associations of Cognitive Function and Education Level With All-Cause Mortality in Adults on Hemodialysis: Findings From the COGNITIVE-HD Study. American Journal of Kidney Diseases, 2019, 74, 452-462.	1.9	24
212	Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association. Journal of Alzheimer's Disease, 2016, 55, 973-979.	2.6	23
213	The ever-stimulating association of smoking and coffee and Parkinson's disease. Annals of Neurology, 2002, 52, 261-262.	5.3	22
214	Are diabetes and amyotrophic lateral sclerosis related?. Nature Reviews Neurology, 2015, 11, 488-490.	10.1	22
215	Referral bias in ALS epidemiological studies. PLoS ONE, 2018, 13, e0195821.	2.5	22
216	Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain, 2022, 145, 276-284.	7.6	22

#	Article	IF	Citations
217	Fructosamine, glycated hemoglobin, and dietary carbohydrates. Clinica Chimica Acta, 2004, 340, 139-147.	1.1	21
218	Association of depression with Alzheimer's disease and vascular dementia in an elderly Arab population of Wadiâ€Ara, Israel. International Journal of Geriatric Psychiatry, 2006, 21, 246-251.	2.7	21
219	Low Incidence of Stroke in Southern Italy. Stroke, 2008, 39, 2923-2928.	2.0	21
220	Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019. Journal of Neurology, 2022, 269, 2080-2098.	3.6	21
221	Dietary Carbohydrates and Glycated Proteins in the Blood in Non Diabetic Subjects. Journal of the American College of Nutrition, 2005, 24, 22-29.	1.8	20
222	Epidemiology of age related hearing loss: A review. Hearing, Balance and Communication, 2015, 13, 77-81.	0.4	20
223	Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 33-39.	1.9	20
224	Brain Abscess: A Need to Screen for Pulmonary Arteriovenous Malformations. Neuroepidemiology, 2005, 24, 76-78.	2.3	19
225	Amyotrophic lateral sclerosis: a new missense mutation in the SOD1 gene. Neurobiology of Aging, 2013, 34, 1709.e3-1709.e5.	3.1	19
226	Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study. European Journal of Neurology, 2016, 23, 1117-1125.	3.3	19
227	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. International Psychogeriatrics, 2016, 28, 1111-1124.	1.0	19
228	Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort. Journal of Neurology, 2017, 264, 2224-2231.	3.6	19
229	Screening for Aphasia in NeuroDegeneration for the Diagnosis of Patients with Primary Progressive Aphasia: Clinical Validity and Psychometric Properties. Dementia and Geriatric Cognitive Disorders, 2018, 46, 243-252.	1.5	19
230	Plasma Î²-amyloid 1â€“42 reference values in cognitively normal subjects. Journal of the Neurological Sciences, 2018, 391, 120-126.	0.6	19
231	Understanding frailty to predict and prevent dementia. Lancet Neurology, The, 2019, 18, 133-134.	10.2	19
232	Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP). Journal of Neurology, 2016, 263, 316-321.	3.6	18
233	Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-based populations. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 659-665.	1.9	18
234	The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurological Sciences, 2021, 42, 1377-1387.	1.9	18

#	Article	IF	Citations
235	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	5.9	18
236	Amyotrophic Lateral Sclerosis: An Aging-Related Disease. Current Geriatrics Reports, 2015, 4, 142-153.	1.1	17
237	Tau aggregation inhibitors: the future of Alzheimerâ€™s pharmacotherapy?. Expert Opinion on Pharmacotherapy, 2016, 17, 457-461.	1.8	17
238	Multicentre, population-based, caseâ€“control study of particulates, combustion products and amyotrophic lateral sclerosis risk. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 854-860.	1.9	17
239	Incidence of dementia in the oldestâ€old and its relationship with age: The Monzino 80â€plus populationâ€based study. Alzheimer's and Dementia, 2020, 16, 472-481.	0.8	17
240	Prevalence of Primary Focal or Segmental Dystonia in Adults in the District of Foggia, Southern Italy: A Service-Based Study. Neuroepidemiology, 2009, 33, 117-123.	2.3	16
241	Nutrition, frailty, and Alzheimer's disease. Frontiers in Aging Neuroscience, 2014, 6, 221.	3.4	16
242	The Use of Antidepressant Medication before and after the Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Cohort Study. Neuroepidemiology, 2015, 44, 91-98.	2.3	16
243	Brain MR Contribution to the Differential Diagnosis of Parkinsonian Syndromes: An Update. Parkinson's Disease, 2016, 2016, 1-27.	1.1	16
244	Critical issues in ALS case-control studies: the case of the Euro-MOTOR study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 411-418.	1.7	16
245	Primary progressive aphasia: a review of neuropsychological tests for the assessment of speech and language disorders. Aphasiology, 2017, 31, 1359-1378.	2.2	16
246	Sensory Changes and the Hearing Lossâ€“Cognition Link. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 127.	2.2	16
247	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 0, , 1-14.	2.1	16
248	Explanation and Elaboration of the Standards of Reporting of Neurological Disorders Checklist: A Guideline for the Reporting of Incidence and Prevalence Studies in Neuroepidemiology. Neuroepidemiology, 2015, 45, 113-137.	2.3	15
249	Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 678-679.	1.9	15
250	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. Expert Opinion on Pharmacotherapy, 2019, 20, 1091-1107.	1.8	15
251	Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Review of Neurotherapeutics, 2019, 19, 397-408.	2.8	15
252	Loss of Swallow Tail Sign on Susceptibility-Weighted Imaging in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2019, 67, 61-65.	2.6	15

#	Article	IF	Citations
253	Mitochondrial genome aberrations in skeletal muscle of patients with motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 261-266.	1.7	14
254	Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1001-1003.	1.9	14
255	Prefrontal Activity and Connectivity with the Basal Ganglia during Performance of Complex Cognitive Tasks Is Associated with Apathy in Healthy Subjects. PLoS ONE, 2016, 11, e0165301.	2.5	14
256	Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinsonâ€™s Disease? The Potential Role of Zolpidem in the Treatment of Parkinsonâ€™s Disease. Parkinson's Disease, 2016, 2016, 1-14.	1.1	13
257	Characteristics and Prognosis of Oldest Old Subjects with Amyotrophic Lateral Sclerosis. Neuroepidemiology, 2017, 49, 64-73.	2.3	13
258	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 259-277.	3.3	13
259	Anticholinergic burden before and after hospitalization in older adults with dementia: Increase due to antipsychotic medications. International Journal of Geriatric Psychiatry, 2019, 34, 868-880.	2.7	13
260	The Reconstructed Cohort Design: A Method to Study Rare Neurodegenerative Diseases in Population-Based Settings. Neuroepidemiology, 2020, 54, 114-122.	2.3	13
261	Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: a doseâ€“response meta-analysis. Journal of Neurology, 2021, 268, 2973-2984.	3.6	13
262	Glycomic and Glycoproteomic Techniques in Neurodegenerative Disorders and Neurotrauma: Towards Personalized Markers. Cells, 2022, 11, 581.	4.1	13
263	Diet and Parkinson's disease. Neurology, 1997, 49, 310-310.	1.1	12
264	Amyotrophic lateral sclerosis and soccer: A different epidemiological approach strengthen the previous findings. Journal of the Neurological Sciences, 2008, 269, 187-188.	0.6	12
265	A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy. Journal of Alzheimer's Disease, 2016, 53, 475-485.	2.6	12
266	FRONTotemporal dementia Incidence European Research Studyâ€”FRONTIERS: Rationale and design. Alzheimer's and Dementia, 2022, 18, 498-506.	0.8	12
267	Autism Spectrum Disorder and Prenatal or Early Life Exposure to Pesticides: A Short Review. International Journal of Environmental Research and Public Health, 2021, 18, 10991.	2.6	12
268	Traditional Old Dietary Pattern of Castellana Grotte (Apulia) Is Associated with Healthy Outcomes. Nutrients, 2020, 12, 3097.	4.1	11
269	COGNITIVE-HD study: protocol of an observational study of neurocognitive functioning and association with clinical outcomes in adults with end-stage kidney disease treated with haemodialysis. BMJ Open, 2015, 5, e009328.	1.9	10
270	Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. Expert Review of Neurotherapeutics, 2016, 16, 1357-1369.	2.8	10

#	Article	IF	Citations
271	High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 843-846.	3.3	10
272	Anti-tau vaccine in Alzheimer's disease: a tentative step. Lancet Neurology, The, 2017, 16, 99-100.	10.2	10
273	Brain Structural Covariance Networks in Behavioral Variant of Frontotemporal Dementia. Brain Sciences, 2021, 11, 192.	2.3	10
274	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
275	Can We Escape Stroke and Alzheimer Disease?. Stroke, 2006, 37, 279-280.	2.0	9
276	Prevention of Late-life Cognitive Disorders: Diet-Related Factors, Dietary Patterns, and Frailty Models. Current Nutrition Reports, 2014, 3, 110-129.	4.3	9
277	Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 77-84.	1.7	9
278	Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia. Cortex, 2019, 117, 257-265.	2.4	9
279	Comparative evaluation of two immunoassays for cerebrospinal fluid Î²-Amyloid1â€“42 measurement. Clinica Chimica Acta, 2019, 493, 107-111.	1.1	9
280	Altered structural brain networks in linguistic variants of frontotemporal dementia. Brain Imaging and Behavior, 2022, 16, 1113-1122.	2.1	9
281	The Role of Hearing Impairment in Cognitive Decline: Need for the Special Sense Assessment in Evaluating Cognition In Older Age. Neuroepidemiology, 2016, 46, 290-291.	2.3	8
282	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. Expert Opinion on Drug Safety, 2017, 16, 1373-1385.	2.4	8
283	The Role of Age on Beta-Amyloid1â€“42 Plasma Levels in Healthy Subjects. Frontiers in Aging Neuroscience, 2021, 13, 698571.	3.4	8
284	The Metabolic Syndrome. Stroke, 2008, 39, 1068-1069.	2.0	7
285	The Role of Graph Theory in Evaluating Brain Network Alterations in Frontotemporal Dementia. Frontiers in Neurology, 0, 13, .	2.4	7
286	The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. Expert Review of Precision Medicine and Drug Development, 2016, 1, 431-442.	0.7	6
287	Classifying change and heterogeneity in amyotrophic lateral sclerosis. Lancet Neurology, The, 2016, 15, 1111-1112.	10.2	6
288	Qualitative analysis of the capacity to consent to treatment in patients with a chronic neurodegenerative disease: Alzheimerâ€™s disease / Analisi qualitativa sulla capacitÃ a prestare consenso al trattamento in pazienti con malattie cronico degenerative neuropsicoorganiche: Demenza di Alzheimer. International Journal of Social Psychiatry, 2018, 64, 26-36.	3.1	6

#	Article	IF	Citations
289	Retinal Vascular Density on Optical Coherence Tomography Angiography and Age-Related Central and Peripheral Hearing Loss in a Southern Italian Older Population. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2169-2177.	3.6	6
290	Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy. GeroScience, 2021, 43, 1003-1014.	4.6	6
291	Comparison of the ability of the Kingâ€™s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 1-9.	1.7	6
292	Imaging correlates of depression in progressive supranuclear palsy. Journal of Neurology, 2022, 269, 3522-3528.	3.6	6
293	Migraine is associated with chest symptoms but not cardiac events. Neurology, 2004, 63, 2209-2210.	1.1	5
294	The Latin American Epidemiology Network for ALS (Laenals). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 372-377.	1.7	5
295	Role of plasma phosphorylated neurofilament heavy chain (pNfH) in amyotrophic lateral sclerosis. Journal of Cellular and Molecular Medicine, 2022, 26, 3608-3615.	3.6	5
296	Radiomics Model for Frontotemporal Dementia Diagnosis Using T1-Weighted MRI. Frontiers in Neuroscience, 0, 16, .	2.8	5
297	Unreported Financial Disclosures in a Study of Migraine and Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2006, 296, 648.	7.4	4
298	I Need to Freeze My Gait. Movement Disorders Clinical Practice, 2015, 2, 440-441.	1.5	4
299	Current Issues in Randomized Clinical Trials of Neurodegenerative Disorders at Enrolment and Reporting: Diagnosis, Recruitment, Representativeness of Patients, Ethnicity, and Quality of Reporting. Frontiers of Neurology and Neuroscience, 2016, 39, 24-36.	2.8	4
300	Amyotrophic lateral sclerosis mortality rates among ethnic groups in a predominant admixed population in Latin America: a population-based study in Ecuador. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 404-412.	1.7	4
301	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
302	Performance of risk prediction scores for cardiovascular mortality in older persons: External validation of the SCORE OP and appraisal. PLoS ONE, 2020, 15, e0231097.	2.5	4
303	The Italian Version of the Test Your Memory (TYM-I): A Tool to Detect Mild Cognitive Impairment in the Clinical Setting. Frontiers in Psychology, 2020, 11, 614920.	2.1	4
304	Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy. Frontiers in Aging Neuroscience, 2021, 13, 629017.	3.4	4
305	Cohort Analysis of 67 Charcot-Marie-Tooth Italian Patients: Identification of New Mutations and Broadening of Phenotype Expression Produced by Rare Variants. Frontiers in Genetics, 2021, 12, 682050.	2.3	4
306	Myoclonic Encephalopathy after Exposure to Trichloroethylene. Industrial Health, 2008, 46, 635-637.	1.0	4

#	Article	IF	Citations
307	Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?. Frontiers in Psychiatry, 2021, 12, 808724.	2.6	4
308	Neuroimaging Findings in a Patient with Anti-IgLON5 Disease: Cerebrospinal Fluid Dynamics Abnormalities. Diagnostics, 2022, 12, 849.	2.6	4
309	Efficacy of riluzole: Who are the patients enrolled in the studies?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 124-125.	2.1	3
310	IN-HOSPITAL MORTALITY OF GENERALIZED CONVULSIVE STATUS EPILEPTICUS: A LARGE US SAMPLE. Neurology, 2008, 70, 1939-1940.	1.1	3
311	Amyotrophic lateral sclerosis: new ideas from cancer. Lancet Neurology, The, 2014, 13, 1067-1068.	10.2	3
312	Early and severe autonomic failure: broadening the clinical phenotype of type-2 spinocerebellar ataxia. A case report. Journal of Neurology, 2015, 262, 224-225.	3.6	3
313	Contribution of Mediterranean Diet in the Prevention of Alzheimerâ€™s Disease. , 2018, , 139-155.		3
314	Early pathological gambling in co-occurrence with semantic variant primary progressive aphasia: a case report . Clinical Interventions in Aging, 2019, Volume 14, 727-733.	2.9	3
315	The importance of maintaining the same order of performance of lung function and SNIP tests in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 337-343.	1.7	3
316	The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. Psychiatry Research, 2022, 308, 114346.	3.3	3
317	Magnetic Resonance Parkinsonism Index Is Associated with REM Sleep Behavior Disorder in Parkinsonâ€™s Disease. Brain Sciences, 2022, 12, 202.	2.3	3
318	Answer to â€œSocial cognition assessment for mild neurocognitive disordersâ€: Alzheimer's and Dementia, 2022, 18, 1441-1442.	0.8	3
319	Amyotrophic lateral sclerosis: A global threat with a possible difference in risk across ethnicities. Neurology, 2007, 68, E17-E17.	1.1	2
320	Ischemic stroke. Neurology, 2010, 75, 1576-1577.	1.1	2
321	Â-Amyloid in CSF: A window into Parkinson disease dementia. Neurology, 2014, 82, 1758-1759.	1.1	2
322	Other Neurocognitive Disorders in Tropical Health (Amyotrophic Lateral Sclerosis and Parkinsonâ€™s) Tj ETQq0 0 0 rgBT /Overlock 10 T		2
323	The Modified Five-Point Test (MFPT): normative data for a sample of Italian elderly. Neurological Sciences, 2021, 42, 2431-2440.	1.9	2
324	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. Alzheimer's and Dementia, 2022, 18, 1957-1968.	0.8	2

#	Article	IF	Citations
325	Decipher nonâ€¢canonical <scp>SPAST</scp> splicing mutations with the help of functional assays in patients affected by spastic paraplegia 4 (<scp>SPG4</scp>). Clinical Genetics, 2022, 102, 155-156.	2.0	2
326	Cerebral Venous Thrombosis after SARS-CoV-2 Infection and Pfizer-BioNTech Vaccination against COVID-19. Diagnostics, 2022, 12, 1253.	2.6	2
327	Blood-cerebrospinal fluid barrier permeability to serum IgG subfractions and measurement of intrathecal IgG synthesis. Journal of the Neurological Sciences, 1986, 73, 325-338.	0.6	1
328	Can dementia be prevented?. BMJ: British Medical Journal, 2010, 341, c4201-c4201.	2.3	1
329	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimerâ€™s disease patients. Future Neurology, 2012, 7, 395-401.	0.5	1
330	Alternative pharmacological treatment options for agitation in Alzheimerâ€™s disease. Geriatric Care, 2015, 1, .	0.2	1
331	How complete is the information on preadmission psychotropic medications in inpatients with dementia? A comparison of hospital medical records with dispensing data. International Journal of Methods in Psychiatric Research, 2018, 27, e1724.	2.1	1
332	Clinical features and genetic characterization of two dizygotic twins with C9orf72 expansion. Neurobiology of Aging, 2018, 69, 293.e1-293.e8.	3.1	1
333	Frontal lobe syndrome and dementias. , 2020, , 617-632.		1
334	Hearing Function: Identification of New Candidate Genes Further Explaining the Complexity of This Sensory Ability. Genes, 2021, 12, 1228.	2.4	1
335	Reduction of Sniff Nasal Inspiratory Pressure (SNIP) as an Early Indicator of the Need of Enteral Nutrition in Patients with Amyotrophic Lateral Sclerosis. Brain Sciences, 2021, 11, 1091.	2.3	1
336	Association Between Migraine and Cardiovascular Disease in Womenâ€”Reply. JAMA - Journal of the American Medical Association, 2006, 296, 2677.	7.4	0
337	Amyotrophic Lateral Sclerosis Descriptive Studies: Not Only Rates and Frequencies. Neuroepidemiology, 2013, 41, 62-63.	2.3	0
338	Systematic Reviews and Meta-Analyses in Neuroepidemiological Research: Applications and Issues. Neuroepidemiology, 2014, 42, 5-6.	2.3	0
339	14th Italian Congress of Neuroepidemiology. Milan, Italy, November 21-22, 2014: Abstracts. Neuroepidemiology, 2014, 43, 155-177.	2.3	0
340	Sensory impairments and cognitive disorders in older age. Geriatric Care, 2017, 3, .	0.2	0
341	Response to Letter to the Editor: â€œPlasma Î²-amyloid1â€“42 reference valuesâ€• Journal of the Neurological Sciences, 2019, 396, 123-124.	0.6	0
342	Prevention of Alzheimerâ€™s disease and dementia: the evidence is out there, but new high-quality studies and implementation are needed. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1140-1141.	1.9	0

#	Article	IF	Citations
343	Neuroepidemiology. , 2022, , 215-225.		0
344	Approach to the patient hospitalized during the Muslim Ramadan: bioethical and clinical considerations. Rivista Di Psichiatria, 2016, 51, 172-176.	0.6	0